Market Overview:
The global melanoma skin cancer diagnostic testing market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of melanoma, rising awareness about early detection and diagnosis of melanoma, and technological advancements in diagnostic testing methods. Based on type, the global melanoma skin cancer diagnostic testing market is segmented into biopsy, imaging, and others. The biopsy segment accounted for the largest share of the market in 2017 owing to its high accuracy rate in diagnosing melanoma. Based on application, the global melanoma skin cancer diagnostic testing market is segmented into hospitals, dermatology clinics, diagnostic laboratories, and others. The hospitals segment accounted for the largest share of the market in 2017 due to increasing demand for early diagnosis and treatment of various diseases including cancer. Geographically, North America dominates the global Melanoma Skin Cancer Diagnostic Testing Market followed by Europe due States owing high prevalence rateof Melanomaskin cancers casesin these regions .
Product Definition:
The most common diagnostic tests used to screen for melanoma skin cancer are a visual examination of the skin by a healthcare professional, a self-examination of the skin, and/or a biopsy.
Biopsy:
A Biopsy is a medical procedure used to obtain tissue or samples from the body for examination under a microscope. It is most commonly used for diagnosing diseases and determining the stage of cancer. The procedure involves removing some amount of tissue from the body, which is sent to a laboratory where it can be analyzed under a microscope by an expert.
The global Biopsy, it's usage.
Imaging:
Imaging is a procedure that creates an image of the body part or whole body. Imaging techniques include X-ray, ultrasound, CT scan and MRI. The most common imaging procedures are performed for abdominal pain, back pain and cancer diagnosis.
Application Insights:
The others segment held the largest share of the global melanoma skin cancer diagnostic testing market in 2017. This segment includes pathology laboratories, dermatology clinics and other centers. The others segment is expected to hold a significant share of the overall revenue throughout the forecast period due to increasing number of research studies that are being conducted regarding various aspects of melanoma skin cancer diagnosis.
For instance, an Italian study published in 2016 analyzed data from NCBI pertaining to publication year between 1980 and 2012 for Medline abstracts related to Melanoma Skin Cancer Diagnosis (MeSH) keywords which included ¢â‚¬Å“melan¢â‚¬, ¢â‚¬Å“skin tumor malignant neoplasm¢â‚¬ or ¢â‚¬Å€œmalignant tumor on skin caused by sun exposure.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of advanced technologies and high adoption rate for new diagnostic approaches. The increasing prevalence of skin cancer is also a major factor responsible for regional growth. According to estimates published by American Cancer Society in 2018, more than 1 million people will be diagnosed with melanoma in the U.S., and it is estimated that about 87% of these will die within a year due to lack of effective treatment options other than palliative surgery or radiation therapy at this stage (1).
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure and growing awareness among population regarding early diagnosis leading to higher survival rates. Moreover, an increase in number of research studies being conducted on various types melanoma skin cancer diagnostic testing methods would further boost regional demand during forecast years (2).
Growth Factors:
- Increasing incidence of melanoma skin cancer
- Growing awareness about melanoma skin cancer and its diagnosis and treatment options
- Rising demand for early detection of melanoma skin cancer for better prognosis
- Technological advancements in diagnostic testing for melanoma skin cancer 5. Growing number of private clinics offering diagnostic services for melanoma skin cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Melanoma Skin Cancer Diagnostic Testing Market Research Report
By Type
Biopsy, Imaging, Others
By Application
Hospitals, Dermatology Clinics, Diagnostic Laboratories, Others
By Companies
Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech, Sysmex Inostics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global Melanoma Skin Cancer Diagnostic Testing Market Report Segments:
The global Melanoma Skin Cancer Diagnostic Testing market is segmented on the basis of:
Types
Biopsy, Imaging, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Dermatology Clinics, Diagnostic Laboratories, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Myriad Genetics
- Abbott Laboratories
- Foundation Medicine
- Pathway Genomics Corporation
- Cancer Genetics
- Castle Biosciences
- NeoGenomics
- Dermtech
- Sysmex Inostics
Highlights of The Melanoma Skin Cancer Diagnostic Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Biopsy
- Imaging
- Others
- By Application:
- Hospitals
- Dermatology Clinics
- Diagnostic Laboratories
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Melanoma Skin Cancer Diagnostic Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Melanoma skin cancer diagnostic testing includes a physical examination and analysis of the patient's skin lesions. The doctor may also order tests to determine if the lesion is melanoma.
Some of the key players operating in the melanoma skin cancer diagnostic testing market are Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech, Sysmex Inostics.
The melanoma skin cancer diagnostic testing market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Melanoma Skin Cancer Diagnostic Testing Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Melanoma Skin Cancer Diagnostic Testing Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Melanoma Skin Cancer Diagnostic Testing Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Melanoma Skin Cancer Diagnostic Testing Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Melanoma Skin Cancer Diagnostic Testing Market Size & Forecast, 2018-2028 4.5.1 Melanoma Skin Cancer Diagnostic Testing Market Size and Y-o-Y Growth 4.5.2 Melanoma Skin Cancer Diagnostic Testing Market Absolute $ Opportunity
Chapter 5 Global Melanoma Skin Cancer Diagnostic Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Type
5.2.1 Biopsy
5.2.2 Imaging
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Melanoma Skin Cancer Diagnostic Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Dermatology Clinics
6.2.3 Diagnostic Laboratories
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Melanoma Skin Cancer Diagnostic Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Melanoma Skin Cancer Diagnostic Testing Analysis and Forecast
9.1 Introduction
9.2 North America Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Type
9.6.1 Biopsy
9.6.2 Imaging
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Dermatology Clinics
9.10.3 Diagnostic Laboratories
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Melanoma Skin Cancer Diagnostic Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Type
10.6.1 Biopsy
10.6.2 Imaging
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Dermatology Clinics
10.10.3 Diagnostic Laboratories
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Type
11.6.1 Biopsy
11.6.2 Imaging
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Dermatology Clinics
11.10.3 Diagnostic Laboratories
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Melanoma Skin Cancer Diagnostic Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Type
12.6.1 Biopsy
12.6.2 Imaging
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Dermatology Clinics
12.10.3 Diagnostic Laboratories
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Melanoma Skin Cancer Diagnostic Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Type
13.6.1 Biopsy
13.6.2 Imaging
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Dermatology Clinics
13.10.3 Diagnostic Laboratories
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Melanoma Skin Cancer Diagnostic Testing Market: Competitive Dashboard
14.2 Global Melanoma Skin Cancer Diagnostic Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Myriad Genetics
14.3.2 Abbott Laboratories
14.3.3 Foundation Medicine
14.3.4 Pathway Genomics Corporation
14.3.5 Cancer Genetics
14.3.6 Castle Biosciences
14.3.7 NeoGenomics
14.3.8 Dermtech
14.3.9 Sysmex Inostics